These assays allows to identify precise cell populations, observe gene expression profiling and focus on biomarkers spatial analysis via Brightplex® multiplex IHC technologies. Our ultimate goal is to deliver to biopharma meaningful insights, gain knowledge in drug mechanism of action and its impact on the immune contexture of the tumor.
Data can be combined into an Immunogram, a multimodal analysis, providing a 360° view of the tumor microenvironment.
Leverage HalioDx know how acquired with Immunoscore®, to propose an enhanced next generation Immunoscore® with multiplex and spatially resolved capabilities for clinical investigations.
The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy
Nature Reviews Cancer
AACR2020 Poster # 870
In the Phase Ib/II trial of TG4001, HalioDx Immunoscore®, Immunosign® and others clinical research service have been performed to assess Immune contexture of patients.
Tumor Infiltrating Lymphocytes (TILs) in triple-negative breast cancer: High Immunoscore is associated with pathological CR in patients receiving neoadjuvant chemotherapy.
High Immunoscore® is associated with good response to neo-adjuvant chemotherapy and prolonged survival in advanced Head and Neck cancer patients.
The Immunoscore: Colon Cancer and Beyond.
Clin Cancer Res.
Immune evasion before tumour invasion in early lung squamous carcinogenesis.
Validation of the Immunoscore prognostic value in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France cohort study (PRODIGE-GERCOR)
Journal of Clinical Oncology
Tumor Immunology and Tumor Evolution: Intertwined Histories
Validation of Brightplex®, a multiplex IHC solution for immune cell phenotyping of the tumor microenvironment
The Immunoscore in the Clinical Practice of Patients with Colon and Rectal Cancers.
HalioDx Biopharma Services
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies.
Nat Rev Drug Discov.
Myeloid-derived suppressor cells (MDSC) assessment using an automated sequential chromogenic multiplex assay (Brightplex®)
Evolution of Metastases in Space and Time under Immune Selection.
T cell exhaustion assessment using an automated sequential chromogenic multiplex assay (Brightplex®)
The immune contexture in cancer prognosis and treatment.
Nat Rev Clin Oncol.
A multiplex immunohistochemistry assay for immune cells profiling on whole FFPE tumor tissue sections
The tumor microenvironment and Immunoscore are critical determinants of dissemination to distant metastasis.
Sci Transl Med.
Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases.
Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer.
The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures.
The immune contexture in human tumours: impact on clinical outcome.
Nat Rev Cancer.